These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 8772089)

  • 41. [Aspects of pathogenetc pharmacotherapy for portal hypertension in liver cirrhosis].
    Garbuzenko DV
    Ter Arkh; 2016; 88(2):101-108. PubMed ID: 27135108
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Complications of portal hypertension in the liver cirrhosis].
    Ivashkin VT
    Ross Fiziol Zh Im I M Sechenova; 2009 Oct; 95(10):1074-92. PubMed ID: 19957897
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Vasoactive factors and hemodynamic mechanisms in the pathophysiology of portal hypertension in cirrhosis.
    Gatta A; Bolognesi M; Merkel C
    Mol Aspects Med; 2008; 29(1-2):119-29. PubMed ID: 18036654
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [The application of non-selective β-blockers, angiotensin receptor antagonists and statins in liver cirrhotic patients].
    Zhang XX; Guo JS
    Zhonghua Gan Zang Bing Za Zhi; 2019 Dec; 27(12):923-928. PubMed ID: 31941254
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Preventing the development of varices in cirrhosis.
    Garcia-Tsao G
    J Clin Gastroenterol; 2007; 41 Suppl 3():S300-4. PubMed ID: 17975480
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Hemodynamics evaluation of the cirrhotic patient with portal hypertension].
    Morales Méndez S; Bernardos Rodríguez A; Salvador-Almeida Reyes D; Tutosaus Gómez JD
    Rev Esp Enferm Apar Dig; 1980 Nov; 58(5):497-504. PubMed ID: 7465961
    [No Abstract]   [Full Text] [Related]  

  • 47. [Cirrhotic cardiomyopathy: prolonged QTc-interval and dyssynchronic electrical and mechanical systole in cirrhosis].
    Henriksen JH; Fuglsang S; Bendtsen F; Christensen E; Møller S
    Ugeskr Laeger; 2004 Aug; 166(35):2995-8. PubMed ID: 15387011
    [No Abstract]   [Full Text] [Related]  

  • 48. Novel use of sildenafil in the treatment of portopulmonary hypertension.
    Chua R; Keogh A; Miyashita M
    J Heart Lung Transplant; 2005 Apr; 24(4):498-500. PubMed ID: 15797756
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Vascular deterioration in cirrhosis: the big picture.
    Bosch J
    J Clin Gastroenterol; 2007; 41 Suppl 3():S247-53. PubMed ID: 17975472
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hemodynamic effects of a combination of prazosin and terlipressin in patients with viral cirrhosis.
    Lee WC; Lin HC; Yang YY; Hou MC; Lee FY; Chang FY; Lee SD
    Am J Gastroenterol; 2001 Apr; 96(4):1210-6. PubMed ID: 11316172
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A1166C angiotensin II type 1 receptor gene polymorphism may predict hemodynamic response to losartan in patients with cirrhosis and portal hypertension.
    Sookoian S; Castaño G; García SI; Viudez P; González C; Pirola CJ
    Am J Gastroenterol; 2005 Mar; 100(3):636-42. PubMed ID: 15743363
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hemodynamic assessment of pharmacological response in the treatment of portal hypertension: a need to know.
    Grace ND
    Am J Gastroenterol; 2000 Aug; 95(8):1862-4. PubMed ID: 10950027
    [No Abstract]   [Full Text] [Related]  

  • 53. [Functional activity of the thrombocytes under conditions of hypersplenism and portal hypertension in liver cirrhosis].
    Makarevich IaA; Kosterova VV; Podobedov GM; Shamshev VM
    Ter Arkh; 1976; 48(3):15-9. PubMed ID: 1006533
    [No Abstract]   [Full Text] [Related]  

  • 54. [Pharmacological modulation of portal hypertension syndrome: current status and future prospects].
    González García M; Albillos Martínez A
    Gastroenterol Hepatol; 2004 Feb; 27 Suppl 1():1-7. PubMed ID: 15195528
    [No Abstract]   [Full Text] [Related]  

  • 55. Portal pressure response to losartan compared with propranolol in patients with cirrhosis.
    De BK; Bandyopadhyay K; Das TK; Das D; Biswas PK; Majumdar D; Mandal SK; Ray S; Dasgupta S
    Am J Gastroenterol; 2003 Jun; 98(6):1371-6. PubMed ID: 12818283
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pathophysiological aspects of pulmonary complications of cirrhosis.
    Møller S; Krag A; Henriksen JH; Bendtsen F
    Scand J Gastroenterol; 2007 Apr; 42(4):419-27. PubMed ID: 17454850
    [No Abstract]   [Full Text] [Related]  

  • 57. Prostaglandin and portal hypertension.
    Guarner C; Soriano G
    Prostaglandins Leukot Essent Fatty Acids; 1993 Mar; 48(3):203-6. PubMed ID: 8469678
    [No Abstract]   [Full Text] [Related]  

  • 58. [Development of the concept of portal hemodynamic change in hepatic cirrhosis and surgical consequences].
    Modiano C
    Osp Ital Chir; 1967 Mar; 16(3):353-8. PubMed ID: 5606246
    [No Abstract]   [Full Text] [Related]  

  • 59. Pathophysiology and management of portal hypertension. 2: Cirrhotic ascites.
    Stanley AJ; Bouchier IA; Hayes PC
    Br J Hosp Med; 1997 Jul 9-Aug 19; 58(2-3):74-8. PubMed ID: 9349370
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Portal hemodynamics in cirrhotics with portal hypertension using color Doppler velocity profile.
    Huang J; Yin X; Lu M; Chen J; Liang L
    Chin Med J (Engl); 1999 Jul; 112(7):627-31. PubMed ID: 11601258
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.